Edwards Lifesciences (EW) Accounts Payables (2009 - 2026)

Edwards Lifesciences has reported Accounts Payables for 18 years, with the latest figure at $181.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 5.05% year-over-year to $181.1 million; the trailing twelve-month figure through Mar 2026 stood at $181.1 million (up 5.05% YoY), and the FY2025 full-year result was $227.5 million, up 15.25% from the prior year.
• Accounts Payables for Q1 2026 stood at $181.1 million, down from $227.5 million in the prior quarter.
• The five-year high for Accounts Payables was $227.5 million in Q4 2025, with the low at $154.9 million in Q3 2022.
• Average Accounts Payables over 5 years is $182.7 million, with a median of $181.1 million recorded in 2026.
• Year-over-year, Accounts Payables slumped 81.13% in 2022 and increased 23.05% in 2023.
• Tracing EW's Accounts Payables over 5 years: stood at $201.9 million in 2022, then declined by 7.58% to $186.6 million in 2023, then climbed by 5.79% to $197.4 million in 2024, then increased by 15.25% to $227.5 million in 2025, then dropped by 20.4% to $181.1 million in 2026.
• The last three Accounts Payables figures came in at $181.1 million (Q1 2026), $227.5 million (Q4 2025), and $165.0 million (Q3 2025), per Business Quant data.

Peer Comparison